Literature DB >> 9822101

Clinical characteristics of sudden death victims in heritable (chromosome 1p1-1q1) conduction and myocardial disease.

S D Nelson1, E A Sparks, H L Graber, H Boudoulas, A A Mehdirad, P Baker, C Wooley.   

Abstract

OBJECTIVES: The purpose of this study was to identify the clinical characteristics of family members at risk of sudden death.
BACKGROUND: The significance of sudden death in heritable cardiac disorders with delayed expression is incompletely understood. Additional insights come from a four-decade experience of seven generations of a family of German origin with autosomal dominant (chromosome 1p1-1q1) cardiac conduction and myocardial disease. METHODS AND
RESULTS: A total of 38 family members (20 males; 18 females) were identified with sudden death. Twenty-eight family members (mean age 48+/-8 years) from earlier generations had no pacemaker at the time of sudden death. In this group, 15 subjects were asymptomatic prior to sudden death. Ten family members with sudden death, from later generations, had chronically implanted pacemakers for high grade atrioventricular block. This group was older (mean age 57+/-2 years), with decreased functional status (New York Heart Association class II to IV), enlarged left atria, dilated left ventricles with reduced systolic function and documented ventricular fibrillation in three members. Twenty-eight family members with sudden death were descendants of sib lineages 2 or 6; 21 family members with sudden death were offspring of a parent who also suffered sudden death.
CONCLUSION: Sudden death is an important late outcome in heritable (chromosome 1p1-1q1) cardiac conduction and myocardial disease. Pacemaker therapy is important for the treatment of symptomatic bradycardia, but it does not prevent sudden death. Family members who are beyond the third decade of life with reduced functional capacity, left ventricular dysfunction, pacemakers and who are the offspring of a parent with sudden death appear to be at greatest risk

Entities:  

Mesh:

Year:  1998        PMID: 9822101     DOI: 10.1016/s0735-1097(98)00424-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

Review 1.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

2.  Sudden cardiac death in a patient with lamin A/C mutation in the absence of dilated cardiomyopathy or conduction disease.

Authors:  Philipp Ehlermann; Stephanie Lehrke; Theano Papavassiliu; Benjamin Meder; Martin Borggrefe; Hugo A Katus; Rainer Schimpf
Journal:  Clin Res Cardiol       Date:  2011-02-16       Impact factor: 5.460

3.  Skeletal myopathy in a family with lamin A/C cardiac disease.

Authors:  Subha Ghosh; Rahul Renapurkar; Subha V Raman
Journal:  Cardiovasc Diagn Ther       Date:  2016-10

Review 4.  Dilated cardiomyopathy.

Authors:  Neal K Lakdawala; Jeffery R Winterfield; Birgit H Funke
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-09-28

Review 5.  Imaging phenotype vs genotype in nonhypertrophic heritable cardiomyopathies: dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.

Authors:  Subha V Raman; Cristina Basso; Harikrishna Tandri; Matthew R G Taylor
Journal:  Circ Cardiovasc Imaging       Date:  2010-11       Impact factor: 7.792

6.  Lamin A/C truncation in dilated cardiomyopathy with conduction disease.

Authors:  Heather M MacLeod; Mary R Culley; Jill M Huber; Elizabeth M McNally
Journal:  BMC Med Genet       Date:  2003-07-10       Impact factor: 2.103

7.  Exome Sequencing Identifies a Novel LMNA Splice-Site Mutation and Multigenic Heterozygosity of Potential Modifiers in a Family with Sick Sinus Syndrome, Dilated Cardiomyopathy, and Sudden Cardiac Death.

Authors:  Michael V Zaragoza; Lianna Fung; Ember Jensen; Frances Oh; Katherine Cung; Linda A McCarthy; Christine K Tran; Van Hoang; Simin A Hakim; Anna Grosberg
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.